Conduit Pharmaceuticals Stock Performance
| CDTTW Stock | 0.01 0 28.16% |
On a scale of 0 to 100, Conduit Pharmaceuticals holds a performance score of 3. The firm shows a Beta (market volatility) of 2.12, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Conduit Pharmaceuticals will likely underperform. Please check Conduit Pharmaceuticals' maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Conduit Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Conduit Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Conduit Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Conduit Pharmaceuticals Taps AI Revolution Major Tech Partnership to Transform Drug Development - StockTitan | 12/12/2024 |
2 | Pre-market Movers CDT, NARI, GDTC, NARI... - RTTNews | 01/07/2025 |
3 | Conduit Pharmaceuticals Inc. Sees Significant Decrease in Short Interest - MarketBeat | 01/28/2025 |
4 | Conduit Pharmaceuticals Awaits Nasdaq Decision on Compliance - TipRanks | 02/19/2025 |
| Begin Period Cash Flow | 597 M | |
| Free Cash Flow | 223 M |
Conduit |
Conduit Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2.00 in Conduit Pharmaceuticals on December 1, 2024 and sell it today you would lose (0.75) from holding Conduit Pharmaceuticals or give up 37.5% of portfolio value over 90 days. Conduit Pharmaceuticals is currently producing 0.8715% returns and takes up 19.1565% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Conduit, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Conduit Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Conduit Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Conduit Pharmaceuticals, and traders can use it to determine the average amount a Conduit Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0455
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CDTTW | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 19.16 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.87 actual daily | 17 83% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Conduit Pharmaceuticals is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Conduit Pharmaceuticals by adding it to a well-diversified portfolio.
Conduit Pharmaceuticals Fundamentals Growth
Conduit Stock prices reflect investors' perceptions of the future prospects and financial health of Conduit Pharmaceuticals, and Conduit Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Conduit Stock performance.
| Return On Asset | -1.09 | ||||
| Revenue | 2.46 B | ||||
| EBITDA | 266.46 M | ||||
| Net Income | 198.41 M | ||||
| Total Debt | 1.23 B | ||||
| Book Value Per Share | (9.50) X | ||||
| Cash Flow From Operations | 344.8 M | ||||
| Total Asset | 3.26 B | ||||
| Retained Earnings | 1.18 B | ||||
| Working Capital | 3.93 M | ||||
About Conduit Pharmaceuticals Performance
Evaluating Conduit Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Conduit Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Conduit Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 73.25 | 65.10 | |
| Return On Tangible Assets | 0.11 | 0.11 | |
| Return On Capital Employed | 0.10 | 0.10 | |
| Return On Assets | 0.06 | 0.06 | |
| Return On Equity | 0.15 | 0.15 |
Things to note about Conduit Pharmaceuticals performance evaluation
Checking the ongoing alerts about Conduit Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Conduit Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Conduit Pharmaceuticals is way too risky over 90 days horizon | |
| Conduit Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Conduit Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Conduit Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Latest headline from news.google.com: Conduit Pharmaceuticals Awaits Nasdaq Decision on Compliance - TipRanks |
- Analyzing Conduit Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Conduit Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Conduit Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Conduit Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Conduit Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Conduit Pharmaceuticals' stock. These opinions can provide insight into Conduit Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.